{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:54:55Z","timestamp":1794246895670,"version":"4.9.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,25]],"date-time":"2024-02-25T00:00:00Z","timestamp":1708819200000},"content-version":"am","delay-in-days":330,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","award":["CO-US-311-4393"],"award-info":[{"award-number":["CO-US-311-4393"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG059501"],"award-info":[{"award-number":["R01AG059501"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016951","name":"UCLA AIDS Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016951","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010296","name":"James B. Pendleton Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010296","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002214","name":"McCarthy Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002214","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.metabol.2022.155395","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T20:10:31Z","timestamp":1673640631000},"page":"155395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Blood immune cells from people with HIV on antiviral regimens that contain tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) have differential metabolic signatures"],"prefix":"10.1016","volume":"141","author":[{"given":"Eleni","family":"Ritou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Satta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Petcherski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Daskou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhav","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hariclea","family":"Vasilopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orian S.","family":"Shirihai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Kelesidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2022.155395_bb0005","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials","volume":"385","author":"Sax","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2022.155395_bb0010","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/QAI.0000000000000940","article-title":"Brief report: a randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results","volume":"72","author":"Wohl","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.metabol.2022.155395_bb0015","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/QAI.0b013e3182965d45","article-title":"Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults","volume":"63","author":"Ruane","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.metabol.2022.155395_bb0020","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/COH.0000000000000680","article-title":"Impact of integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV","volume":"16","author":"Lake","year":"2021","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.metabol.2022.155395_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052562","article-title":"Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis","volume":"8","author":"Messiaen","year":"2013","journal-title":"PLoS One."},{"issue":"Suppl 2","key":"10.1016\/j.metabol.2022.155395_bb0030","doi-asserted-by":"crossref","first-page":"M1","DOI":"10.1177\/135965350501002S01","article-title":"Mitochondria, HIV infection and its treatment: where do we go from here?","volume":"10","author":"Cossarizza","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1016\/j.metabol.2022.155395_bb0035","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/493413","article-title":"Role of mitochondria in HIV infection and associated metabolic disorders: focus on nonalcoholic fatty liver disease and lipodystrophy syndrome","volume":"2013","author":"Perez-Matute","year":"2013","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.metabol.2022.155395_bb0040","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/cddis.2012.47","article-title":"Mitochondrial DNA: a proinflammatory 'enemy from within' during HIV infection?","volume":"3","author":"Pinti","year":"2012","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.metabol.2022.155395_bb0045","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.freeradbiomed.2011.01.019","article-title":"Mitochondrial complex I impairment in leukocytes from type 2 diabetic patients","volume":"50","author":"Hernandez-Mijares","year":"2011","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.metabol.2022.155395_bb0050","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/1358863X14521315","article-title":"Relation of mitochondrial oxygen consumption in peripheral blood mononuclear cells to vascular function in type 2 diabetes mellitus","volume":"19","author":"Hartman","year":"2014","journal-title":"Vasc Med"},{"key":"10.1016\/j.metabol.2022.155395_bb0055","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.diabet.2007.10.011","article-title":"Mitochondrial DNA oxidation and manganese superoxide dismutase activity in peripheral blood mononuclear cells from type 2 diabetic patients","volume":"34","author":"Garcia-Ramirez","year":"2008","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.metabol.2022.155395_bb0060","first-page":"10","article-title":"The impact of HIV- and ART-induced mitochondrial dysfunction in cellular senescence and aging","author":"Schank","year":"2021","journal-title":"Cells."},{"key":"10.1016\/j.metabol.2022.155395_bb0065","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2337\/db12-1219","article-title":"Methods for assessing mitochondrial function in diabetes","volume":"62","author":"Perry","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2022.155395_bb0070","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.redox.2013.12.026","article-title":"A review of the mitochondrial and glycolytic metabolism in human platelets and leukocytes: implications for their use as bioenergetic biomarkers","volume":"2","author":"Kramer","year":"2014","journal-title":"Redox Biol"},{"key":"10.1016\/j.metabol.2022.155395_bb0075","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1097\/QAD.0000000000001238","article-title":"Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection","volume":"30","author":"Kelesidis","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.metabol.2022.155395_bb0080","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.antiviral.2017.01.014","article-title":"Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures","volume":"140","author":"Stray","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1016\/j.metabol.2022.155395_bb0085","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/BJ20110162","article-title":"Assessing mitochondrial dysfunction in cells","volume":"435","author":"Brand","year":"2011","journal-title":"Biochem J"},{"key":"10.1016\/j.metabol.2022.155395_bb0090","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/B978-0-12-801415-8.00016-3","article-title":"Analysis and interpretation of microplate-based oxygen consumption and pH data","volume":"547","author":"Divakaruni","year":"2014","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.metabol.2022.155395_bb0095","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/ilar.43.4.207","article-title":"Sample size determination","volume":"43","author":"Dell","year":"2002","journal-title":"ILAR J"},{"key":"10.1016\/j.metabol.2022.155395_bb0100","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ab.2017.07.009","article-title":"Mitochondrial membrane potential","volume":"552","author":"Zorova","year":"2018","journal-title":"Anal Biochem"},{"issue":"542\u201355","key":"10.1016\/j.metabol.2022.155395_bb0105","article-title":"Mitochondria-endoplasmic reticulum contact sites function as immunometabolic hubs that orchestrate the rapid recall response of memory CD8(+) T cells","volume":"48","author":"Bantug","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.metabol.2022.155395_bb0110","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nature13312","article-title":"Metabolism of stromal and immune cells in health and disease","volume":"511","author":"Ghesquiere","year":"2014","journal-title":"Nature"},{"issue":"490\u2013503","key":"10.1016\/j.metabol.2022.155395_bb0115","article-title":"Etomoxir inhibits macrophage polarization by disrupting CoA homeostasis","volume":"28","author":"Divakaruni","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2022.155395_bb0120","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.3389\/fimmu.2018.02489","article-title":"Human dendritic cell subsets undergo distinct metabolic reprogramming for immune response","volume":"9","author":"Basit","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.metabol.2022.155395_bb0125","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1023\/A:1026445108136","article-title":"Bioenergetics of human peripheral blood mononuclear cell metabolism in quiescent, activated, and glucocorticoid-treated states","volume":"20","author":"Schmid","year":"2000","journal-title":"Biosci Rep"},{"key":"10.1016\/j.metabol.2022.155395_bb0130","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMoa031314","article-title":"Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes","volume":"350","author":"Petersen","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155395_bb0135","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nri.2017.99","article-title":"The spectrum of T cell metabolism in health and disease","volume":"18","author":"Bantug","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.metabol.2022.155395_bb0140","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1080\/15548627.2021.1972403","article-title":"Autophagy-dependent glutaminolysis drives superior IL21 production in HIV-1-specific CD4 T cells","volume":"18","author":"Loucif","year":"2022","journal-title":"Autophagy"},{"key":"10.1016\/j.metabol.2022.155395_bb0145","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1080\/15548627.2021.1874134","article-title":"Lipophagy confers a key metabolic advantage that ensures protective CD8A T-cell responses against HIV-1","volume":"17","author":"Loucif","year":"2021","journal-title":"Autophagy"},{"key":"10.1016\/j.metabol.2022.155395_bb0150","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus two different prodrugs of tenofovir to treat HIV","volume":"381","author":"Venter","year":"2019","journal-title":"N Engl J Med"},{"issue":"56","key":"10.1016\/j.metabol.2022.155395_bb0155","first-page":"280","article-title":"Reversibility of renal dysfunction after discontinuation of tenofovir","volume":"2016","author":"Cha","year":"2003","journal-title":"J Am Pharm Assoc"},{"key":"10.1016\/j.metabol.2022.155395_bb0160","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/nrd1201","article-title":"Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective","volume":"2","author":"Lewis","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.metabol.2022.155395_bb0165","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/labinvest.2009.14","article-title":"Tenofovir renal toxicity targets mitochondria of renal proximal tubules","volume":"89","author":"Kohler","year":"2009","journal-title":"Lab Invest"},{"key":"10.1016\/j.metabol.2022.155395_bb0170","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3389\/fnagi.2017.00281","article-title":"Astrocyte senescence and metabolic changes in response to HIV antiretroviral therapy drugs","volume":"9","author":"Cohen","year":"2017","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.metabol.2022.155395_bb0175","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.mad.2018.07.008","article-title":"HIV antiretroviral therapy drugs induce premature senescence and altered physiology in HUVECs","volume":"175","author":"Cohen","year":"2018","journal-title":"Mech Ageing Dev"},{"key":"10.1016\/j.metabol.2022.155395_bb0180","doi-asserted-by":"crossref","DOI":"10.1172\/JCI148013","article-title":"Alveolar macrophages from persons living with HIV show impaired epigenetic response to mycobacterium tuberculosis","volume":"131","author":"Correa-Macedo","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2022.155395_bb0185","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10863-014-9583-7","article-title":"Sex differences in mitochondrial (dys)function: implications for neuroprotection","volume":"47","author":"Demarest","year":"2015","journal-title":"J Bioenerg Biomembr"},{"key":"10.1016\/j.metabol.2022.155395_bb0190","first-page":"1013","article-title":"The women's interagency HIV study: an observational cohort brings clinical sciences to the bench","volume":"12","author":"Bacon","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.metabol.2022.155395_bb0195","first-page":"169","article-title":"Flow cytometry has a significant impact on the cellular metabolome","volume":"18","author":"Binek","year":"2019","journal-title":"J Proteome Res"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049522002736?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049522002736?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T02:37:27Z","timestamp":1777430247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049522002736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":39,"alternative-id":["S0026049522002736"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2022.155395","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blood immune cells from people with HIV on antiviral regimens that contain tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) have differential metabolic signatures","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2022.155395","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"155395"}}